1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1984
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1976
Pneumocystis pneumonia in patients with cancer: clinical setting.
DeVita V, Goodell B, Hubbard S, Geelhoed G, Young R. Pneumocystis pneumonia in patients with cancer: clinical setting. National Cancer Institute Monograph 1976, 43: 41-7. PMID: 1087959.Peer-Reviewed Original ResearchConceptsPneumocystis pneumoniaClinical settingTreated with combination chemotherapyDevelopment of Pneumocystis pneumoniaWithdrawal of chemotherapyCombination chemotherapyClinical remissionHematologic malignanciesEmpirical treatmentSolid tumorsInfectious deathCancer patientsPatientsPentamidine isethionatePneumoniaAcute formChemotherapyTumorCancerRemissionUncontrolled growthMalignancyPneumocystisA Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug dose
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research